Skip to the main content.

1 min read

Liomont Signs Commercial License Agreement with Selexis SA for Use of Proprietary Cell Line and SUREtechnology Platform

Geneva, Switzerland, 2 June 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, announced today that Laboratorios Liomont, SA (Liomont), a leading Mexico City-based pharmaceutical company, has entered into a commercial license agreement for the use of Selexis’ technology and proprietary CHO-K1 cell line.

Under the agreement, Liomont will have use of the Selexis CHO-M Cell Line™ and the SUREtechnology Platform for the development, manufacture and commercialization of an undisclosed antibody. Financial terms were not disclosed.

“We at Selexis look forward to seeing Liomont’s progress to clinical studies,” said Yemi Onakunle, PhD, vice president, licensing and business development, Selexis SA. “Our SUREtechnology Platform, based on quality science and research coming from our Swiss laboratories, has the power to facilitate rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum. We are proud to add Liomont to our list of active commercial partners.”

“The productivity and speed of stable cell line generation with the SUREtechnology Platform will be vital to Liomont as we seek to advance our program into clinical development,” said Sergio Valentinotti, PhD, Director of Life Sciences, Liomont. “By leveraging the SUREtechnology Platform, we were able to improve our titers by several fold, which is one step closer to potentially bringing important biologics to Mexico.”

About Laboratorios Liomont

Liomont is a 100 percent Mexican pharmaceutical company established in 1938, ranked number 8 in the national pharmaceutical market in units and 16 in value in 2014, with high quality prescription and OTC products. It has one of the most dynamic growth rates in the market. Liomont has a capacity of more than 120 million units per year in a high tech facility considered to be one of the most modern in Latin America. It has approximately 1500 employees of which more than half are medical sales reps with the aim of creating a solid and collaborative team. In addition to marketing activities, Liomont has the social mission to be a source of employment, training and development of its people to ensure a better quality of life. The Company has received the Socially Responsible Company Award for 10 continuous years due to its outstanding commitment to society. Other public and private institutions have also recognized several initiatives in business and ecology among others.


At KBI Biopharma, our PUREplatform™ is everything you need to make a protein. Catered to your needs, our service package contains plasmids, strains,...

Read More

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors,...

Read More

Accelerating the development of life-changing biological medicines in a new European state-of-the art facility

Biopharmaceutical companies are increasingly seeking service providers to help them reduce biologics manufacturing risks while increasing the speed...

Read More